Armed with fresh - and positive – top-line Phase III results, Sunovion Pharmaceuticals Inc. has confirmed it will file its attention-deficit hyperactivity disorder (ADHD) drug dasotraline this year for use in both adults and pediatric populations despite lingering clouds over its potential in older patients.
Sunovion said it took the decision in light of positive top-line results evaluating dasotraline in children aged between six and 12 with
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?